Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants — ALTEA

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Psoriatic Arthritis (PsA) Clinical Trial

Official title:
Abatacept - Long-Term Real-Life Experience in Psoriatic Arthritis (PsA) in Germany: an Observational Study (ALTEA)

Status Completed

Clinical Trial Summary

The purpose of this study is a long-term, observational study of Abatacept in patients with Psoriatic Arthritis, a chronic inflammatory disorder.

n/a

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01692912` - Psoriatic Arthritis Treat to Target vs. Usual Care	N/A
Terminated	`NCT02775656` - UCB Cimzia Pregnancy Follow-up Study
Active, not recruiting	`NCT03671148` - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)	Phase 3
Active, not recruiting	`NCT05421442` - A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
Recruiting	`NCT04541810` - A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis